MX2007000327A - Tratamiento del linfoma de celulas b. - Google Patents

Tratamiento del linfoma de celulas b.

Info

Publication number
MX2007000327A
MX2007000327A MX2007000327A MX2007000327A MX2007000327A MX 2007000327 A MX2007000327 A MX 2007000327A MX 2007000327 A MX2007000327 A MX 2007000327A MX 2007000327 A MX2007000327 A MX 2007000327A MX 2007000327 A MX2007000327 A MX 2007000327A
Authority
MX
Mexico
Prior art keywords
antibody
treatment
patients
regimen
nhl
Prior art date
Application number
MX2007000327A
Other languages
English (en)
Spanish (es)
Inventor
Werner Krause
Joachim Kalmus
Jens Kuhlmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007000327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of MX2007000327A publication Critical patent/MX2007000327A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007000327A 2004-07-09 2005-07-07 Tratamiento del linfoma de celulas b. MX2007000327A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58641404P 2004-07-09 2004-07-09
PCT/EP2005/007213 WO2006005477A1 (en) 2004-07-09 2005-07-07 Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma

Publications (1)

Publication Number Publication Date
MX2007000327A true MX2007000327A (es) 2007-03-12

Family

ID=34972426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007000327A MX2007000327A (es) 2004-07-09 2005-07-07 Tratamiento del linfoma de celulas b.

Country Status (13)

Country Link
US (2) US20060029543A1 (https=)
EP (1) EP1765399A1 (https=)
JP (2) JP2008505148A (https=)
KR (1) KR101250127B1 (https=)
AU (1) AU2005261923B2 (https=)
BR (1) BRPI0513007A (https=)
CA (1) CA2568526C (https=)
IL (1) IL179636A (https=)
MX (1) MX2007000327A (https=)
NO (1) NO344366B1 (https=)
RU (1) RU2394596C2 (https=)
WO (1) WO2006005477A1 (https=)
ZA (1) ZA200701158B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8061104B2 (en) 2005-05-20 2011-11-22 Valinge Innovation Ab Mechanical locking system for floor panels
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
US11055552B2 (en) * 2016-01-12 2021-07-06 Disney Enterprises, Inc. Systems and methods for detecting light signatures and performing actions in response thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
DK0752248T3 (da) * 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
WO2000059473A1 (en) * 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
EP1567863A4 (en) 2002-11-22 2007-10-03 Nuvelo Inc THERAPY AND DIAGNOSTIC PROCEDURES

Also Published As

Publication number Publication date
AU2005261923A1 (en) 2006-01-19
RU2007104839A (ru) 2008-08-20
NO20070763L (no) 2007-02-08
IL179636A0 (en) 2007-05-15
BRPI0513007A (pt) 2008-04-22
RU2394596C2 (ru) 2010-07-20
US20060029543A1 (en) 2006-02-09
NO344366B1 (no) 2019-11-18
ZA200701158B (en) 2008-09-25
CA2568526C (en) 2015-11-03
EP1765399A1 (en) 2007-03-28
JP6034314B2 (ja) 2016-11-30
WO2006005477A1 (en) 2006-01-19
US20190112383A1 (en) 2019-04-18
AU2005261923B2 (en) 2010-11-18
JP2008505148A (ja) 2008-02-21
CA2568526A1 (en) 2006-01-19
KR20070042527A (ko) 2007-04-23
IL179636A (en) 2013-09-30
KR101250127B1 (ko) 2013-04-02
JP2014080429A (ja) 2014-05-08

Similar Documents

Publication Publication Date Title
Geyer Jr et al. Survival with trastuzumab emtansine in residual HER2-positive breast cancer
CN100389825C (zh) 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者
Nademanee et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
Knox et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Schwartzberg Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma
US20190112383A1 (en) Treatment of b-cell lymphoma
Gregory et al. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
Tyson et al. Current status and future of relapsed primary central nervous system lymphoma (PCNSL)
Hagenbeek et al. Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin®) in lymphoma
Kushner et al. Coordinated use of sequentially escalated cyclophosphamide and cell-cycle-specific chemotherapy (N4SE protocol) for advanced neuroblastoma: experience with 100 patients.
Coffey et al. Therapy of non-Hodgkin's lymphoma
WO2025180474A1 (zh) 一种二价双特异性抗体、抗体偶联核素药物及其应用
Tang et al. Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second‐look resection
Zinzani et al. Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice–Report of a European workshop
Hicsönmez et al. High remission rate in acute myeloblastic leukemia in children treated with high‐dose methylprednisolone
Freedman et al. Initial treatment of advanced stage (III/IV) follicular lymphoma
Chen et al. Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma
Furman et al. Testicular relapse in children with acute nonlymphoblastic leukemia
Theodossiou et al. Non-Hodgkin's lymphomas
Russell et al. Combination chemotherapy of metastatic breast cancer with vincristine, adriamycin and prednisolone
Visani et al. Autologous stem cell transplantation for aggressive lymphomas
RU2739107C1 (ru) Способ диагностики рака желудка с гиперэкспрессией Her2/neu
Uleer et al. Long-term partial remission with capecitabine/trastuzumab in a patient with metastatic breast cancer following progression on trastuzumab alone
AU2005211669B2 (en) Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody
Freedman Non–Transplant-Related Treatment Options in Follicular Lymphoma

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted
HC Change of company name or juridical status

Owner name: HIGH POINT PHARMACEUTICALS, LLC